Today's Rundown Can the price be right? With the world watching, Gilead faces a no-win decision on remdesivir Healthcare jobs declined by 1.4M in April as physician practices shed 243,000 jobs Cadila shutters Indian ingredients plant after 26 workers test positive for COVID-19: report Payer experts: Why COVID-19 will 'fundamentally' change care delivery Gilead hit with Iranian cyberattack for role in COVID-19 response: report Healthcare roundup: Express Scripts caps prescription costs on thousands of drugs for newly uninsured Biopharma roundup: Gilead reportedly hit by Iranian hackers; NIH launches new remdesivir-Olumiant trial Federal agency finds 'reasonable grounds to believe' Rick Bright's whistleblower claims: NYT FDA publishes first validation results of 12 COVID-19 antibody tests Early missteps, transparency questions dog U.S. government's remdesivir rollout: reports CVS is adapting its strategy for specialty pharmacy for COVID-19. Here's how Sorrento ventures into COVID-19 with Mount Sinai antibody pact Allscripts withdraws financial outlook for 2020 due to uncertainty from COVID-19 pandemic Featured Story | | | Thursday, May 7, 2020 The world is waiting for Gilead Sciences to set a price tag for remdesivir, the first brand-new med authorized to treat COVID-19. Its choice will affect Gilead's reputation and bottom line, set a tone for follow-up meds—and either help polish up the pharma industry's image or create a new flashpoint for criticism. |
|
|---|
|
Top Stories Friday, May 8, 2020 Healthcare jobs have declined by a massive 1.4 million in April as physician offices struggle with plummeting patient volume due to COVID-19. Friday, May 8, 2020 Global drugmakers are working overtime to keep supplies coming amid the novel coronavirus pandemic. But in manufacturing facilities packed with workers, COVID-19 presents a particularly difficult challenge—and now one Indian plant has been forced to shutter due to a rash of infections. Thursday, May 7, 2020 As the country begins to emerge from the COVID-19 pandemic, what will the “new normal” look like? Health insurance industry experts say to expect a continued focus on telehealth. Friday, May 8, 2020 Gilead Sciences has captured worldwide attention with its COVID-19 antiviral, remdesivir, cleared late last week by the FDA—not all of it welcome. With bad actors targeting companies at the head of the spear in the pandemic response, Gilead may have found itself in their sights. Friday, May 8, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Friday, May 8, 2020 Gilead Sciences, maker of a newly authorized COVID-19 antiviral drug, may have been targeted by Iranian hackers phishing for passwords . The NIH will test that drug, remdesivir, alongside Eli Lilly's anti-inflammatory drug Olumiant. The FDA has results from a first batch of diagnostic quality tests. And more. Friday, May 8, 2020 Only days after former BARDA chief Rick Bright filed a whistleblower complaint alleging retaliation by the Trump administration, the U.S. Office of the Special Counsel has recommended his temporary reinstatement, the New York Times reports. Friday, May 8, 2020 The FDA published results from the first batch of COVID-19 antibody diagnostics to have their accuracy independently evaluated by federal laboratories—starting with the 12 blood tests the agency has already authorized for emergency use against the pandemic. Friday, May 8, 2020 When Gilead Sciences scored a groundbreaking FDA emergency use authorization for COVID-19 therapy remdesivir, the company made the unusual move of handing distribution rights to the U.S. government. But the federal rollout has gotten off to a rocky start. Friday, May 8, 2020 Specialty pharmacy patients are among healthcare’s most vulnerable, and protecting them from COVID-19 has meant moving full speed ahead in growing digital solutions. Friday, May 8, 2020 Sorrento Therapeutics is jumping into the race to develop therapies against COVID-19, teaming up with Mount Sinai to develop a cocktail of antibodies from the blood of 15,000 recovered patients. The company's scientists believe their multipronged therapy will sidestep risks such as treatment resistance. Thursday, May 7, 2020 Allscripts's first-quarter revenue was down $7 million to $10 million due to the impact of lower patient volumes for its provider clients amid the COVID-19 pandemic. The electronic health record vendor reported revenue of $417 million in the first quarter of 2020, down 3% from revenue of $432 million during the same quarter last year. |
